TY - JOUR
T1 - Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
AU - Allevi, G.
AU - Strina, C.
AU - Andreis, D.
AU - Zanoni, V.
AU - Bazzola, L.
AU - Bonardi, S.
AU - Foroni, C.
AU - Milani, M.
AU - Cappelletti, M. R.
AU - Gussago, F.
AU - Aguggini, S.
AU - Giardini, R.
AU - Martinotti, M.
AU - Fox, S. B.
AU - Harris, A. L.
AU - Bottini, A.
AU - Berruti, A.
AU - Generali, D.
PY - 2013/4/30
Y1 - 2013/4/30
N2 - Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response.Patients and methods:This single institution study comprised 120 oestrogen receptor (ER)-positive postmenopausal women with primary breast cancer (clinical stage ≥T2, N0-1), from three sequential cohorts (cohort A of 40, cohort B of 40 and cohort C of 40 patients, respectively) based on different duration of the neoadjuvant letrozole. Biological markers such as ER, progesterone receptor, HER2 and Ki-67 expression were tested at diagnosis and at definitive surgery.Results:A total of 89 patients (75.4%) achieved an objective response with 44 (37.3%) clinical CRs and 45 (38.1%) partial responses. The clinical CRs were significantly observed in cohort C (23 out of 40 patients, 57.5%) and B (16 out of 38 patients, 42.1%) compared with cohort A (5 out of 40 patients, 12.5%) (P-value for trend
AB - Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response.Patients and methods:This single institution study comprised 120 oestrogen receptor (ER)-positive postmenopausal women with primary breast cancer (clinical stage ≥T2, N0-1), from three sequential cohorts (cohort A of 40, cohort B of 40 and cohort C of 40 patients, respectively) based on different duration of the neoadjuvant letrozole. Biological markers such as ER, progesterone receptor, HER2 and Ki-67 expression were tested at diagnosis and at definitive surgery.Results:A total of 89 patients (75.4%) achieved an objective response with 44 (37.3%) clinical CRs and 45 (38.1%) partial responses. The clinical CRs were significantly observed in cohort C (23 out of 40 patients, 57.5%) and B (16 out of 38 patients, 42.1%) compared with cohort A (5 out of 40 patients, 12.5%) (P-value for trend
UR - http://www.scopus.com/inward/record.url?scp=84877010367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877010367&partnerID=8YFLogxK
U2 - 10.1038/bjc.2013.151
DO - 10.1038/bjc.2013.151
M3 - Article
C2 - 23579222
AN - SCOPUS:84877010367
VL - 108
SP - 1587
EP - 1592
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 8
ER -